Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation

Seminars in Immunology

Volumn 23, Issue 3, 2011, Pages 157-164

  Wojciechowski, David ^a   Vincenti, Flavio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Belatacept; Costimulation; Kidney transplant

Indexed keywords

ABATACEPT; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; CALCINEURIN; CALCINEURIN INHIBITOR; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; INTERLEUKIN 2; MYCOPHENOLIC ACID; RAPAMYCIN; T LYMPHOCYTE RECEPTOR;

ACUTE GRAFT REJECTION; ANTIGEN PRESENTING CELL; APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; GRAFT SURVIVAL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; ORGAN TRANSPLANTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD28; GRAFT REJECTION; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; ORGAN TRANSPLANTATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 80052901571     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2011.07.002     Document Type: Review

References (54)

1. Bretscher P.A. A two-step: two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci USA 1999, 96(1):185-190.
2. Van Parijs L., Abbas A.K. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998, 280(5361):243-248.
3. Yamada A., Salama A.D., Sayegh M.H. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002, 13(2):559-575.
4. Sayegh M.H., Turka L.A. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998, 338(25):1813-1821.
5. Kirk A.D., Burkly L.C., Batty D.S., Baumgartner R.E., Berning J.D., Buchanan K., et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999, 5(6):686-693.
6. Andre P., Prasad K.S., Denis C.V., He M., Papalia J.M., Hynes R.O., et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002, 8(3):247-252.
7. Alegre M.L., Frauwirth K.A., Thompson C.B. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001, 1(3):220-228.
8. McAdam A.J., Schweitzer A.N., Sharpe A.H. The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev 1998, 165:231-247.
9. Kim K.S., Denton M.D., Chandraker A., Knoflach A., Milord R., Waaga A.M., et al. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am J Pathol 2001, 158(3):977-986.
10. Vanhove B., Laflamme G., Coulon F., Mougin M., Vusio P., Haspot F., et al. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 2003, 102(2):564-570.
11. Shiao S.L., McNiff J.M., Masunaga T., Tamura K., Kubo K., Pober J.S. Immunomodulatory properties of FK734: a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities. Transplantation 2007, 83(3):304-313.
12. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006, 355(10):1018-1028.
13. Judge T.A., Tang A., Spain L.M., Deans-Gratiot J., Sayegh M.H., Turka L.A. The in vivo mechanism of action of CTLA4Ig. J Immunol 1996, 156(6):2294-2299.
14. Pearson T.C., Alexander D.Z., Winn K.J., Linsley P.S., Lowry R.P., Larsen C.P. Transplantation tolerance induced by CTLA4-Ig. Transplantation 1994, 57(12):1701-1706.
15. Webb L.M., Walmsley M.J., Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol 1996, 26(10):2320-2328.
16. Larsen C.P., Pearson T.C., Adams A.B., Tso P., Shirasugi N., Strobert E., et al. Rational development of LEA29Y (belatacept): a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005, 5(3):443-453.
17. Lenschow D.J., Zeng Y., Thistlethwaite J.R., Montag A., Brady W., Gibson M.G., et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 1992, 257(5071):789-792.
18. Latek R., Fleener C., Lamian V., Kulbokas E., Davis P.M., Suchard S.J., et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 2009, 87(6):926-933.
19. Genovese M.C., Becker J.C., Schiff M., Luggen M., Sherrer Y., Kremer J., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005, 353(11):1114-1123.
20. Kremer J.M., Westhovens R., Leon M., Di Giorgio E., Alten R., Steinfeld S., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349(20):1907-1915.
21. Meier-Kriesche H.U., Schold J.D., Srinivas T.R., Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004, 4(3):378-383.
22. United Network for Organ Sharing National Data, 2008 [accessed 22.11.10.]. http://www.unos.org/.
23. Jevnikar A.M., Mannon R.B. Late kidney allograft loss: what we know about it, and what we can do about it. Clin J Am Soc Nephrol 2008, 3(Suppl 2):S56-S67.
24. System, USRD, USRDS 2008 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States, 2008. http://www.usrds.org/adr.htm.
25. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Allen R.D., Chapman J.R. The natural history of chronic allograft nephropathy. N Engl J Med 2003, 349(24):2326-2333.
26. Gaston R.S., Cecka J.M., Kasiske B.L., Fieberg A.M., Leduc R., Cosio F.C., et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010, 90(1):68-74.
27. Ducloux D., Motte G., Kribs M., Abdelfatah A.B., Bresson-Vautrin C., Rebibou J.M., et al. Hypertension in renal transplantation: donor and recipient risk factors. Clin Nephrol 2002, 57(6):409-413.
28. Mathis A.S., Davé N., Knipp G.T., Friedman G.S. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 2004, 61(6):565-585. [quiz 586-7].
29. Vincenti F., Friman S., Scheuermann E., Rostaing L., Jenssen T., Campistol J.M., et al. Results of an international: randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007, 7(6):1506-1514.
30. Vincenti F., Kirkman R., Light S., Bumgardner G., Pescovitz M., Halloran P., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation, Daclizumab Triple Therapy Study Group. N Engl J Med 1998, 338(3):161-165.
31. Vincenti F., Ramos E., Brattstrom C., Cho S., Ekberg H., Grinyo J., et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001, 71(9):1282-1287.
32. Halloran P.F. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004, 351(26):2715-2729.
33. Vincenti F., Larsen C., Durrbach A., Wekerle T., Nashan B., Blancho G., et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005, 353(8):770-781.
34. Vincenti1 F., Charpentier B., Vanrenterghem Y., Rostaing L., Bresnahan B., Darji P., et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010, 10(3):535-546.
35. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130(6):461-470.
36. Durrbach A., Pestana J.M., Pearson T., Vincenti F., Garcia V.D., Campistol J., et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010, 10(3):547-557.
37. Larsen C.G.J., Charpentier B., Medina Pestana J., Kamar N., Vanrenterghem Y., Lin C.S., et al. Belatacept vs. cyclosporine in kidney transplant recipients: two year outcomes from the benefit study. Am J Transplant 2010, 10(Suppl 4):1.
38. Durrbach A.L., Medina Pestana C.P., Vanrenterghem J., Vincenti Y., Florman F., Xing S., et al. Belatacept vs. cyclosporine in ECD kidney transplants: two-year outcomes from the BENEFIT-EXT study. Am J Transplant 2010, 10(Suppl. 4):1.
39. Gill J.S, Tonelli M., Mix C.H., Pereira B.J. The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol 2003, 14:1636-1642.
40. Opelz G., Wujciak T., Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998, 53(1):217-222.
41. Mange K.C., Cizman B., Joffe M., Feldman H.I. Arterial hypertension and renal allograft survival. JAMA 2000, 283(5):633-638.
42. Kasiske B.L., Anjum S., Shah R., Skogen J., Kandaswamy C., Danielson B., et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004, 43(6):1071-1081.
43. Wissing K.M., Abramowicz D., Broeders N., Vereerstraeten P. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 2000, 70(3):464-472.
44. Everly M.J., Everly J.J., Arend L.J., Brailey P., Susskind B., Govil A., et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009, 9(5):1063-1071.
45. Opelz G., Dohler B. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation 2008, 85(5):661-666.
46. Racusen L.C., Colvin R.B., Solez K., Mihatsch M.J., Halloran P.F., Campbell P.M., et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003, 3(6):708-714.
47. Tanaka T., Kyo M., Kokado Y., Takahara S., Hatori M., Suzuki K., et al. Correlation between the Banff 97 classification of renal allograft biopsies and clinical outcome. Transplant Int 2004, 17(2):59-64.
48. Vereerstraeten P., Abramowicz D., de Pauw L., Kinnaert P. Absence of deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recovery. Transplantation 1997, 63(12):1739-1743.
49. Adams A.B., Pearson T.C., Larsen C.P. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev 2003, 196:147-160.
50. Lakkis F.G., Sayegh M.H. Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol 2003, 14(9):2402-2410.
51. Li X.C., Rothstein D.M., Sayegh M.H. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev 2009, 229(1):271-293.
52. Bluestone J.A., Liu W., Yabu J.M., Laszik Z.G., Putnam A., Belingheri M., et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008, 8(10):2086-2096.
53. Ferguson R., Grinyó J., Vincenti F., Kaufman D.B., Woodle E.S., Marder B.A., et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2010.
54. Rostaing L.N., del G., Rial C., Steinberg M., Vincenti S., Shi F., et al. Switch from a CNI- to a belatacept-based immunosuppressive regimen in kidney transplant recipients is safe and results in better renal function: 12 month results from a Phase II study. Am J Transplant 2010, 10(Suppl. 4):1.